{"id":397905,"date":"2025-05-21T01:05:00","date_gmt":"2025-05-20T23:05:00","guid":{"rendered":"https:\/\/medizinonline.com\/inibidores-da-pcsk9-evidencias-actuais-mecanismos-e-questoes-em-aberto\/"},"modified":"2025-05-21T02:39:16","modified_gmt":"2025-05-21T00:39:16","slug":"inibidores-da-pcsk9-evidencias-actuais-mecanismos-e-questoes-em-aberto","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/pt-pt\/inibidores-da-pcsk9-evidencias-actuais-mecanismos-e-questoes-em-aberto\/","title":{"rendered":"Inibidores da PCSK9: Evid\u00eancias actuais, mecanismos e quest\u00f5es em aberto"},"content":{"rendered":"\n<p><strong>O tromboembolismo venoso (TEV), que consiste na trombose venosa profunda (TVP) e na embolia pulmonar (EP), \u00e9 a terceira causa mais comum de mortalidade cardiovascular em todo o mundo, a seguir ao enfarte do mioc\u00e1rdio e ao acidente vascular cerebral. Apesar dos progressos cont\u00ednuos na anticoagula\u00e7\u00e3o, continua a faltar uma estrat\u00e9gia preventiva espec\u00edfica contra o TEV que v\u00e1 para al\u00e9m da anticoagula\u00e7\u00e3o. Nos \u00faltimos anos, foi demonstrado que o tromboembolismo arterial e venoso partilham mais factores de risco comuns do que se supunha anteriormente, incluindo a dislipidemia e os processos inflamat\u00f3rios.  <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Finibidores-da-pcsk9-evidencias-actuais-mecanismos-e-questoes-em-aberto%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>O tromboembolismo venoso (TEV), que consiste na trombose venosa profunda (TVP) e na embolia pulmonar (EP), \u00e9 a terceira causa mais comum de mortalidade cardiovascular em todo o mundo, a&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Finibidores-da-pcsk9-evidencias-actuais-mecanismos-e-questoes-em-aberto%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":397908,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Preven\u00e7\u00e3o do tromboembolismo venoso","footnotes":""},"category":[11367,11521,11524,11551],"tags":[18165,20560,20557,33951,18606,27489],"powerkit_post_featured":[],"class_list":["post-397905","post","type-post","status-publish","format-standard","has-post-thumbnail","category-cardiologia-pt-pt","category-estudos","category-formacao-continua","category-rx-pt","tag-colesterol","tag-ldl-pt-pt","tag-pcsk9-pt-pt","tag-quatro-aniversario","tag-thromboembolismo-pt-pt","tag-trombose","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-19 15:59:47","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"pt_PT","wpml_translations":{"es_ES":{"locale":"es_ES","id":397900,"slug":"inhibidores-de-la-pcsk9-pruebas-actuales-mecanismos-y-cuestiones-abiertas","post_title":"Inhibidores de la PCSK9: Pruebas actuales, mecanismos y cuestiones abiertas","href":"https:\/\/medizinonline.com\/es\/inhibidores-de-la-pcsk9-pruebas-actuales-mecanismos-y-cuestiones-abiertas\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/397905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=397905"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/397905\/revisions"}],"predecessor-version":[{"id":401528,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/397905\/revisions\/401528"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media\/397908"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=397905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/category?post=397905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=397905"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/powerkit_post_featured?post=397905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}